Genomic polymorphism, growth properties, and immunologic variations in human herpesvirus-6 isolates

Ablashi, Dharam V.; Balachandran, N.; Josephs, S.F.; Hung, Chia Chun; Krueger, G. R. F.; Kramarsky, Bernhard; Salahuddin, S. Z.; Gallo, Robert C.

doi:10.1016/0042-6822(91)90424-a

Cited by 279 publications

(145 citation statements)

References 26 publications

Supporting

Mentioning

141

Contrasting

Order By: Relevance

“…4 and 5). Clearly there are at least two groups of strain variants, group A or U1102-like and group B or Z29-or KF-like, in agreement with earlier findings on re- striction enzyme polymorphisms and antigenic differences (Schirmer et al, 199t ;Ablashi et al, 1991). These clusters contain very closely related strains showing nucleotide differences of only 4 to 6 %.…”

Section: Relationships Between Hhv-6 Strain Variants and With Other Hsupporting

confidence: 78%

“…Reference laboratory strains were collected from both the A and B groups which had been identified by antigenic differences and restriction enzyme site polymorphisms (Schirmer et al, 1991 ;Ablashi et al, 1991). These are Ull02-1ike strains, or group A, including Ul102, GS and AJ, and Z29-1ike strains, or group B, including Z29 and KF.…”

Section: Resultsmentioning

confidence: 99%

“…There appear to be some growth differences between the groups, although these may be strain-specific. Comparative studies show growth of some isolates in different CD4 + T leukaemic cell lines: group A isolates in HSB2 cells, and group B isolates in MOLT3 cells (Wyatt et al, 1990;Ablashi et al, 1991;Schirmer et al, 1991;Chandran et al, 1992;Dewhurst et al, 1992). It has been suggested that the HHV-6 strain variant groups be reclassified (Schirmer et al, 1991), but the molecular basis of the grouping has not been determined and therefore it is not clear whether this represents variation between strains or new species.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Two groups of human herpesvirus 6 identified by sequence analyses of laboratory strains and variants from Hodgkin's lymphoma and bone marrow transplant patients

Gompels

Carrigan

Carss

et al. 1993

Journal of General Virology

View full text Add to dashboard Cite

Fifteen human herpesvirus 6 (HHV-6) strain variants were analysed by PCR amplifications, restriction enzyme site polymorphism and sequence analyses. Three DNA regions were chosen for study: a fragment of a variable glycoprotein gene (210 bp), the conserved glycoprotein H (gH) gene complete with intergenic sequences (2381 bp) and the 5' intergenic region with the Nterminal coding sequence of gH up to a polymorphic BamHI site (427 bp). Infected cell DNA from five laboratory reference strains including GS, Ul102, AJ, Z29 and KF were examined together with DNA from peripheral blood lymphocytes infected with HHV-6 reactivated from blood and/or marrow from five bone marrow transplant (BMT) patients. Separate blood and marrow isolates were obtained from four BMT patients. In addition, HHV-6 sequences were examined directly from one of six Hodgkin's lymphomas and six B cell proliferations which contained HHV-6 DNA as detected by PCR amplification. The results show two groups of very closely related but heterogeneous strains which correlate with previous groupings by antigenic and restriction site differences. These are variant A strains (including laboratory strains GS, Ul102 and AJ) and variant B strains (including laboratory strains Z29 and KF, the Hodgkin's lymphoma strain, and the nine BMT patient isolates). Variations between the groups were 4 to 6 % in nucleotide sequence and 5 to 8.5 % in amino acid sequence. Within each group maximum heterogeneity was observed in different genes. Variant A strains differed by 2-0% in the variable glycoprotein gene sequence whereas variant B strains were identical in this region; conversely, variant B strains differed by 2 to 3 % in the gH N-terminal and intergenic sequences whereas variant A strains differed there by less than 0'2%. There was evidence for sequence drift independent of selection: relationships between the groups were shown by analyses of amino acid sequence, coding nucleotide sequence as well as intergenic sequence, and the B variant-specific BamHI site in the gH gene was due to a non-coding nucleotide substitution. There was little evidence for in vivo or in vitro variation: the gH nucleotide sequence from the uncultured lymphoma strain (first variant B gH gene identified) was almost identical to the gH sequence from four BMT isolates, and matched BMT isolates from blood and marrow were identical or with a single nucleotide substitution. The overall variation observed between the HHV-6 strain groups was similar or less than that seen between human cytomegalovirus strains such as AD169 or Towne, but deafly distinct from the much greater divergence between currently designated herpesvirus species.

show abstract

Section: Relationships Between Hhv-6 Strain Variants and With Other Hsupporting

confidence: 78%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Two groups of human herpesvirus 6 identified by sequence analyses of laboratory strains and variants from Hodgkin's lymphoma and bone marrow transplant patients

Gompels

Carrigan

Carss

et al. 1993

Journal of General Virology

View full text Add to dashboard Cite

show abstract

“…In particular, a distinct increase in HHV-6 reactivation and encephalitis following CBT (compared with HSCT with other stem cell sources) has emerged in the recent literature. 10,11 HHV-6 is the collective name for HHV-6A and HHV-6B, 12,13 two closely related beta-herpesviruses that establish primary infection in early childhood and maintain lifelong persistent infection with a combined seroprevalence of 490% in adults. [14][15][16][17] Of the two, HHV-6B is the variant implicated in nearly all documented cases of HHV-6 reactivation following HSCT, which typically occurs within 30 days of HSCT.…”

Section: Introductionmentioning

confidence: 99%

HHV-6 encephalitis in umbilical cord blood transplantation: a systematic review and meta-analysis

Scheurer

Pritchett

Amirian

et al. 2012

Bone Marrow Transplant

106

View full text Add to dashboard Cite

Reactivation of human herpesvirus-6 (HHV-6) frequently occurs following hematopoietic SCT (HSCT), and has been associated with clinical consequences in many patient populations. HHV-6 reactivation and HHV-6 encephalitis seem to occur more frequently in patients undergoing HSCT with cord blood (CB) as the stem cell source. We have conducted a systematic literature review and meta-analysis to investigate the clinical significance of this correlation. A systematic review of publications indexed in PubMed was performed for HSCT studies published over the past 10 years that fit inclusion criteria. Data on prevalences of HHV-6 reactivation and HHV-6 encephalitis post HSCT were abstracted from 19 papers. Meta-analyses were conducted to calculate combined prevalence estimates. The prevalences of HHV-6 reactivation and encephalitis were compared among CB vs non-CB HSCT. Prevalences of HHV-6 reactivation and HHV-6 encephalitis were significantly higher in patients receiving CB as the stem cell source than in patients receiving another stem cell source (72.0% vs 37.4%, Po0.0001; 8.3% vs 0.50%, Po0.0001, respectively). HHV-6 reactivation and HHV-6 encephalitis are significant complications in the post-HSCT setting, particularly in patients receiving CB as the stem cell source. Thus, patients undergoing umbilical CB transplantation should be closely monitored for HHV-6 reactivation.

show abstract

“…12 Immunologic and molecular studies based on restriction enzyme mapping analysis, reactivity to HHV-6-specific monoclonal antibodies, and in vitro growth characteristics have led to the distinction of two major variants, designated A and B. 13 Bone marrow transplant recipients more often harbor the B variant of HHV-6. 14,15 After BMT the virus can be isolated from peripheral blood cells in 40-60% of recipients.…”

mentioning

confidence: 99%

Human herpesvirus 6 is an important pathogen in infectious lung disease after allogeneic bone marrow transplantation

Buchbinder

Elmaagacli

Schaefer

et al. 2000

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Two hundred and ten bronchoalveolar lavage (BAL) samples were obtained from 50 patients 10 days before and on defined days after allogeneic bone marrow transplantation (BMT). The samples were examined for human cytomegalovirus (HCMV) and human herpesvirus-6 (HHV-6) by polymerase chain reaction (PCR). Fifteen patients (30%) had a positive result for HCMV in at least one sample and 25 (50%) were positive for HHV-6 in at least one sample. Five patients developed HCMV-associated interstitial pneumonia (HCMV-IP) within 100 days after allogeneic BMT. Four of these patients were positive for both HCMV and HHV-6. Conspicuous HHV-6 positivity was detected in BAL samples obtained because of respiratory symptoms. No association was found between detection of HHV-6 and acute graft-versus-host disease. Engraftment failure or a delay in engraftment was observed in none of the 50 patients. The data from this study indicate that HHV-6 is a pathogen in HCMV-associated, as well as in non-HCMV-associated infectious lung disease after BMT. Bone Marrow Transplantation (2000) 26, 639-644.

show abstract

Genomic polymorphism, growth properties, and immunologic variations in human herpesvirus-6 isolates

Cited by 279 publications

References 26 publications

Two groups of human herpesvirus 6 identified by sequence analyses of laboratory strains and variants from Hodgkin's lymphoma and bone marrow transplant patients

Two groups of human herpesvirus 6 identified by sequence analyses of laboratory strains and variants from Hodgkin's lymphoma and bone marrow transplant patients

HHV-6 encephalitis in umbilical cord blood transplantation: a systematic review and meta-analysis

Human herpesvirus 6 is an important pathogen in infectious lung disease after allogeneic bone marrow transplantation

Contact Info

Product

Resources

About